Literature DB >> 22691837

Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis.

Richard Harding1, Kathleen M Foley, Stephen R Connor, Ernesto Jaramillo.   

Abstract

Multidrug-resistant (MDR) tuberculosis is costly, difficult to treat, and poses a global threat to tuberculosis control. The high burden of disease and treatment for patients, poor cure rates, and high mortality bring distress to patients, families, and caregivers. Despite guidance to improve treatment outcomes, little attention has been paid to palliative care of patients and families, such as for physical, psychosocial, social, and spiritual difficulties. An international expert symposium was convened to articulate an appropriate palliative care response for people with MDR tuberculosis. Several policies should be updated to ensure that palliative and end-of-life care is in place alongside treatment should cure be achieved, and to the end of life if not. Many services have been developed that exemplify integrated palliative care (ie, provided from within existing tuberculosis care). We recommend that existing expertise within palliative care can be used, which will improve management of problems such as dyspnoea, cachexia, and haemoptysis for patients across care settings, including at home, and enhance performance of control programmes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22691837     DOI: 10.1016/S1473-3099(12)70084-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  6 in total

1.  Effects of ascent to high altitude on human antimycobacterial immunity.

Authors:  Sarah Eisen; Louise Pealing; Robert W Aldridge; Mark J Siedner; Alejandro Necochea; Inna Leybell; Teresa Valencia; Beatriz Herrera; Siouxsie Wiles; Jon S Friedland; Robert H Gilman; Carlton A Evans
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

2.  Palliative care for patients with HIV/AIDS admitted to intensive care units.

Authors:  Paola Nóbrega Souza; Erique José Peixoto de Miranda; Ronaldo Cruz; Daniel Neves Forte
Journal:  Rev Bras Ter Intensiva       Date:  2016-09

3.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

4.  What palliative care-related problems do patients with drug-resistant or drug-susceptible tuberculosis experience on admission to hospital? A cross-sectional self-report study.

Authors:  Richard Harding; Kath Defilippi; David Cameron
Journal:  Palliat Med       Date:  2016-07-28       Impact factor: 4.762

5.  Place of death for people with HIV: a population-level comparison of eleven countries across three continents using death certificate data.

Authors:  Richard Harding; Stefano Marchetti; Bregje D Onwuteaka-Philipsen; Donna M Wilson; Miguel Ruiz-Ramos; Maria Cardenas-Turanzas; YongJoo Rhee; Lucas Morin; Katherine Hunt; Joan Teno; Cecilia Hakanson; Dirk Houttekier; Luc Deliens; Joachim Cohen
Journal:  BMC Infect Dis       Date:  2018-01-25       Impact factor: 3.090

6.  A public health approach to palliative care in the response to drug resistant TB: an ethnographic study in Bengaluru, India.

Authors:  Joseph M Sawyer; Rahul Asgr; Florence N Todd Fordham; John D H Porter
Journal:  BMC Palliat Care       Date:  2018-10-31       Impact factor: 3.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.